Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSX: MSCL )

0.8800 +0.0100 (+1.15%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 207,094
Open 0.8800
Bid (Size) 0.8600 (120)
Ask (Size) 0.8800 (205)
Prev. Close 0.8700
Today's Range 0.8400 - 0.8800
52wk Range 0.3800 - 1.320
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
From Satellos Bioscience Inc.
Via Business Wire

Performance

YTD
+57.14%
+57.14%
1 Month
+25.71%
+25.71%
3 Month
+87.23%
+87.23%
6 Month
+69.23%
+69.23%
1 Year
+57.14%
+57.14%

More News

Read More
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
From Satellos Bioscience Inc.
Via Business Wire
Satellos Appoints Stephanie Brown to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Satellos Reports Q3 2024 Financial Results and Provides Clinical Update
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in November 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Participation in September 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
From Satellos Bioscience Inc.
Via Business Wire
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at Upcoming Virtual Investor Conferences in March and April
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
From Satellos Bioscience Inc.
Via Business Wire
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Recognized as a Top 50 TSX Venture Exchange Company
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.